Bringing breakthrough pioneering therapies to patients with life-threatening diseases.
Our key facts and figures
2 technological platforms in immuno-oncology (autologous & allogeneic).
3 study assets in pre-clinical and clinical development (CAR-T NKR-2,CAR-T NKR-3 and B7H6).
Phase I trial
1 phase I trial completed in the US for our CAR-T NKR-2 immuno-oncology program. No safety issue reported.
Phase Ib trial
THINK trial initiated to evaluate safety and efficacy of CAR-T NKR-2 cells in 7 indications, both hematological (AML, MM) and solid malignancies (bladder, ovarian, breast, pancreas and colorectal).
3 international collaborations with Dartmouth College (USA), Institut Curie (France) and ONO Pharmaceutical Co., Ltd (Japan).
Phase III trial
CHART-1, the European Phase III clinical trial evaluating the efficacy of C-Cure, our lead cardiology candidate, has been completed. Celyad is now looking for a partner to further develop and commercialize the product.
of staff dedicated
82% of staff dedicated to R&D activities.
3 stock listings on Euronext Brussels, Paris and NASDAQ.